Welcome to TheraCryf plc

Leading the way in brain health and orphan disease.

TheraCryf plc is a clinical stage biotechnology developing a new generation of innovative therapeutics in brain health and related orphan diseases with a focus on behavioural brain disorders and oncology.

Formerly Evgen Pharma plc, TheraCryf acquired Chronos Therapeutics in April 2024.  Evgen’s clinical development of sulforaphane-based medicines complements Chronos’ neuropsychiatry assets and has the expertise to develop and commercialise the combined portfolio.




Our Pipeline

As the leading clinical drug development company working to harness the scientific potential of sulforaphane, Evgen is focused on developing commercially successful products. We are currently targeting certain cancers and inflammatory diseases.
Read more +


Evgen’s strategy is to demonstrate proof of concept for its proprietary drug candidates in carefully selected diseases and then conclude partnerships with larger organisations better positioned to take these drugs through to commercial launch.


Evgen’s lead compound, SFX-01, is a patent-protected complex of sulforaphane and alpha-cyclodextrin, our Sulforadex® technology. Clinical trials with SFX-01 demonstrate its potential in inhibiting tumour and cancer stem cells, as well as addressing other unmet clinical needs.

Meet the team

Our experienced team share a passion for advancing the potential of SFX-01 in providing effective treatments that improve patient outcomes. Together, our expertise spans biotech, preclinical and clinical drug development, commercialisation, business development, finance and investment.

News & Media

Read about Evgen’s developments in our regulatory news and latest media articles.


Find out more by viewing our corporate documents, presentations and scientific publications.